Evaluation of the Protective Efficacy of Different Doses of a <i>Chlamydia abortus</i> Subcellular Vaccine in a Pregnant Sheep Challenge Model for Ovine Enzootic Abortion
Morag Livingstone,
Kevin Aitchison,
Javier Palarea-Albaladejo,
Francesca Chianini,
Mara Silvia Rocchi,
Sergio Gastón Caspe,
Clare Underwood,
Allen Flockhart,
Nicholas Wheelhouse,
Gary Entrican,
Sean Ranjan Wattegedera,
David Longbottom
Affiliations
Morag Livingstone
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Kevin Aitchison
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Javier Palarea-Albaladejo
Biomathematics and Statistics Scotland, JCMB, The King’s Buildings, Edinburgh EH9 3FD, UK
Francesca Chianini
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Mara Silvia Rocchi
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Sergio Gastón Caspe
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Clare Underwood
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Allen Flockhart
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Nicholas Wheelhouse
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Gary Entrican
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Sean Ranjan Wattegedera
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
David Longbottom
Moredun Research Institute, Pentlands Science Park, Bush Loan, Midlothian EH26 0PZ, UK
Chlamydia abortus causes the disease ovine enzootic abortion, which is one of the most infectious causes of foetal death in small ruminants worldwide. While the disease can be controlled using live and inactivated commercial vaccines, there is scope for improvements in safety for both sheep and human handlers of the vaccines. We have previously reported the development of a new prototype vaccine based on a detergent-extracted outer membrane protein preparation of C. abortus that was determined to be more efficacious and safer than the commercial vaccines when administered in two inoculations three weeks apart. In this new study, we have developed this vaccine further by comparing its efficacy when delivered in one or two (1 × 20 µg and 2 × 10 µg) doses, as well as also comparing the effect of reducing the antigen content of the vaccine by 50% (2 × 5 µg and 1 × 10 µg). All vaccine formulations performed well in comparison to the unvaccinated challenge control group, with no significant differences observed between vaccine groups, demonstrating that the vaccine can be administered as a single inoculation and at a lower dose without compromising efficacy. Future studies should focus on further defining the optimal antigen dose to increase the commercial viability of the vaccine.